Coeptis Therapeutics Holdings Business Summary

Coeptis Therapeutics Holdings, Inc. (COEP) operates as a dual-sector enterprise following its transformational merger with Z Squared Inc. in early 2026. The company generates primary revenue through institutional-scale digital asset mining, specifically securing the Dogecoin (DOGE) and Litecoin (LTC) networks using a fleet of approximately 9,800 ASIC miners across facilities in the Carolinas and Iowa. This technology infrastructure segment, valued at roughly $660 million, provides recurring revenue through contracted hosting and mining operations. Simultaneously, the company is executing a strategic spin-out of its legacy biopharmaceutical division—valued at $75 million—which focuses on allogeneic cell therapy platforms including SNAP-CAR, GEAR, and the clinical-stage NK cell therapy DVX201. Within the market, Coeptis distinguishes itself as the largest publicly traded pure-play Dogecoin miner, competing directly with digital infrastructure firms like Marathon Digital Holdings and Riot Platforms, while maintaining a unique biotech optionality that separates it from traditional pharmaceutical peers such as Shattuck Labs and Coherus BioSciences. The leadership team is led by Co-founder, Chairman, and CEO David Mehalick, who brings over 30 years of experience across life sciences, investment banking, and technology. Key executive roles are held by Chief Financial Officer Brian Cogley, a veteran of corporate finance in the pharmaceutical sector, and Co-founder Christine Sheehy, who serves as VP of Compliance and Corporate Secretary with extensive experience in global drug commercialization. Following the Z Squared merger, the board was expanded to include digital asset experts David Halabu and Michelle Burke, alongside newly appointed members Bryan Fuerst, Adam Sohn, and Kenneth Cooper. The company maintains a notable institutional investor base, including significant positions held by The Vanguard Group, Geode Capital Management, and Renaissance Technologies, reflecting its shift toward a high-growth technology infrastructure and diversified life sciences model.